CEL-SCI Corp (CVM) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results
May 8, 2015 5:00 PM EDTVIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2015.
Recent key clinical developments include:
Reported new record high patient enrollment numbers - 24 patients in January, 25 patients in February and 29 patients in March in the Phase III head and neck cancer trial; with continued increase post-Q2 of 31 patients in April A total of four hundred thirty-seven (437) patients have been enrolled in the Phase III study as of April 30, 2015. Trial received clearance in Romania, the... More